Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Determine how much voriconazole is absorbed when the product is given by mouth to children
with extensive graft versus host disease after a stem cell transplantation and determine the
correct dosing of voriconazole in this population.
Hypothesis: Children with gastrointestinal graft versus host disease will have decreased
absorption of oral voriconazole and require higher doses of voriconazole in order to prevent
or treat fungal infections.
Phase:
Phase 1
Details
Lead Sponsor:
Phillip Brian Smith
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)